Physician profile
Michael Serlin
NPI 1568488336
$29,961.72
in general payments reported to CMS, 2019-2025
13 companies · $6,316 in 2025
The $6,316 reported for 2025 was more than what 91% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,992 · 2020: $412 · 2021: $3,690 · 2022: $8,404 · 2023: $5,069 · 2024: $1,079 · 2025: $6,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $1,213 · Travel and Lodging: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,575.98 |
| Food and Beverage | $1,212.79 |
| Travel and Lodging | $675.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $23,725.25 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $4,296.16 | 2019-2025 | Biktarvy |
| Cepheid | $440.00 | 2021 | |
| Janssen Biotech, INC. | $409.30 | 2019-2022 | |
| Abbvie INC. | $400.72 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $333.49 | 2019-2025 | Pifeltro, Capvaxive, Delstrigo |
| Janssen Products, Lp | $199.98 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $56.11 | 2020-2021 | |
| Global Blood Therapeutics, INC. | $29.76 | 2021 | |
| Novo Nordisk INC | $20.44 | 2025 | Ozempic |
| Indivior INC. | $20.03 | 2025 | Sublocade |
| Theratechnologies INC. | $15.80 | 2019 | |
| Braeburn INC. | $14.68 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Serlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.